Target of the project was the recovery of a critical innovation project and the safeguarding of internal technology transfer.

• Medical engineering start-up company, approx. 140 employees
• Approx. 100 Mio. EUR seed-phase investment
• Enterprise target: development of a measuring system for blood glucose with significantly higher measuring accuracy
• Product does not meet specified performance requirements
• Market entry dates had been repeatedly postponed

• Redesign of project structure and planning with regard to fastest possible market entry
• Interim project lead
• Identification of improvement levers to achieve specified product performance
• Technology and know-how transfer between development site and production plant

• Restructuring of project team ,rescheduling of project timing plan, effective task tracking
• Installation of cross-functional task forces
• Direct operational project team lead and intensive project and risk controlling
• Bi-weekly status reporting towards supervisory board and investors
• Acceptance of functional and disciplinary responsibility (R&D manager, plant manager, quality manager)

• CE-approval of the product with marketable accuracy
• Significant increase in production yield
• Identification of additional improvement levers for second generation product performance
• Establishing contacts to additional investors for subsequent financing